|
【结 构 式】 
|
【药物名称】TRK-710 【化学名称】(SP-4-3)-[3-Acetyl-5(S)-methyl-2,4(3H,5H)-furandionato-O3,O4][1(R),2(R)-cyclohexanediamine-N,N']platinum(1+) salt with 3-acetyl-5(S)-methyl-2,4(3H,5H)-furandione (1:1) 【CA登记号】173903-27-0, 180981-07-1 (cation), 173903-41-8 (hexafluorophosphate salt), 173903-42-9 (perchlorate salt), 173903-35-0 (tetraflu 【 分 子 式 】C20H28N2O8Pt 【 分 子 量 】619.54476 |
【开发单位】Toray (Originator) 【药理作用】Oncolytic Drugs, Platinum Complexes |
合成路线1
TRK-710 was synthesized by reaction of [1(R),2(R)-cyclohexanediamine-N,N']dihydroxoplatinum(II), (I), with 3-acetyl-5(S)-methyltetrahydrofuran-2,4-dione (II) in water.
| 【1】 Hoshi, A.; Castañer, J.; TRK-710. Drugs Fut 1997, 22, 1, 38. |
| 【2】 Hata, G.; Mutoh, M.; Hashimoto, H. (Toray Industries, Inc.); Novel platinum(II) complex and drug for treating malignant tumor. EP 0457921; JP 1991500696; US 5302587; WO 9109041 . |
合成路线2
TRK-710 was synthesized by reaction of the platinum complex (I) with 3-acetyl-4-hydroxy-5(S)-methylfuran-2(5H)-one (II) by means of silver sulfate and barium hydroxide in water.
| 【1】 Kawai, H.; et al.; Synthesis and platinum complexes containing 3-acyltetronic acid derivatives as ligand and its antitumor activity. Symp Med Chem 1999, Abst 2P-21. |